Troubled generics’ firm Wockhardt is set to raise US$100 million via its foreign currency convertible bonds (FCCBs). However, fellow Indian generics’ manufacturer, Sun Pharma, has objected to the deal, amongst much speculation as to what Sun Pharma’s intentions are.
Sun Pharma blocks Wockhardt settlement
Home/Pharma News | Posted 17/09/2010 0 Post your comment
At a time when Wockhardt is about to strike a deal with several offshore creditors, Sun Pharma has stepped in, claiming that it holds close to 20% of the FCCBs that Wockhardt had issued to raise the US$100 million.
The action by Sun Pharma may delay the new agreement Wockhardt was planning to enter with some of the other FCCB investors. Sun Pharma insists that it is “purely a financial investment by Sun Pharma Global” and that they “are not interested in acquiring Wockhardt or any of its assets”. According to Sun Pharma, “several lenders, including a public sector bank, are opposing the inadequate settlement terms”.
However, a Wockhardt spokesperson said most of the investors are backing the settlement proposed by the company, which has taken months of negotiations.
Reference
Wockhardt Press Release. Sun Pharma subsidiary receives warning letter from USFDA. 31 August 2010.
Guidelines
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
Policies & Legislation
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
Comments (0)
Post your comment